Unrelated Donor Transplant for Malignant and Non-Malignant Disorders

Inclusion Criteria: * Adequate renal function defined as: serum creatinine 2.0 x normal, or creatinine clearance or radioisotope GFR \> 40 ml/min/m2 or \> 40 ml/min/1.73 m2 or an equivalent GFR as determined by the institutional normal range. * Adequate liver function defined as: total bilirubin \< 2.5 x normal; or SGOT (AST) or SGPT (ALT) \< 5.0 x normal. * Adequate cardiac function defined as: shortening fraction of \> 25% by echocardiogram, or ejection fraction of \> 40% by radionuclide angiogram or echocardiogram. * Adequate pulmonary function defined as: DLCO \> 35% by pulmonary function test. For children who are uncooperative, no evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry \> 94% in room air. * Diseases: * CML (CP, AP or BC) * AML/MDS/JCML * ALL * Lymphoma (Hodgkin's and non-Hodgkin's) * Non-malignant disorders * Bone Marrow Failure Syndromes: Patients with the following diagnoses are eligible: * Severe Aplastic Anemia: * Fanconi Anemia * Severe Congenital Neutropenia (Kostmann's Syndrome) * Amegakaryocytic Thrombocytopenia * Diamond-Blackfan Anemia * Infantile Osteopetrosis * Schwachman-Diamond Syndrome * Dyskeratosis Congenita * Other bone marrow failure syndromes at discretion of Principal Investigator * Immunodeficiencies: * SCIDS, all subtypes * Combined Immunodeficiency Syndrome * Wiskott-Aldrich syndrome * Chronic Granulomatous Disease * Chediak-Higashi Syndrome * Leukocyte Adhesion Deficiency * Other immunodeficiencies at discretion of Principal Investigator * Inborn Errors of Metabolism (IEOM): * Transplant is recommended for the following disorders: Hurler syndrome (L-iduronidase deficiency, MPS-I), Maroteaux-Lamy syndrome (galactosamine-4-sulfatase deficiency, MP VI), Sly syndrome (glucuronidase deficiency, MPS-VII), Globoid cell Leukodystrophy (galactocerebrosidasedeficiency), Metachromatic leukodystrophy (arylsulfatase A deficiency), Childhood-onset X-linked adrenoleukodystrophy (X-ALD), Fucosidosis (fucosidase deficiency), Mannosidosis, Aspartylglucosaminuria, Niemann-Pick Disease Type B (acid sphingomyelinase deficiency), Gaucher disease (glucocerebrosidase deficiency) Type I (non neuropathic), Other diagnoses may be considered at the discretion of the Principal Investigator * For X-ALD patients greater than 5 years of age, IQ \> 80 is required. For other patients greater than 5 years of age, IQ \> 70 is required. * For patients less than 5 years of age, the developmental quotient or clinical neurodevelopmental examination should demonstrate potential for stabilization at a level of functioning where continuous life support (e.g. mechanical ventilation) would not be predicted to be required in the year following transplantation. * Histiocytosis: * Hemophagocytic Lymphohistiocytosis (HLH) * Familial Erythrophagocytic Lymphohistiocytosis * Langerhans Cell Histiocytosis * Malignant Histiocytosis * Other Malignant and non-malignant diseases: Other malignant and non-malignant diseases not listed above may be eligible if deemed appropriate by the Principal Investigator. Exclusion Criteria: * Women who are pregnant and/or breast feeding are ineligible